drugset
drugset / Trial / NCT05146882

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

NCT05146882 ↗

Phase 2 Withdrawn Dicerna Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.

Timeline

Start
2021-12
Primary completion
2022-05-23
Completion
2022-05-23

Outcome

Outcome not reported

Stopped (Enrollment): “Update to Program Design - No Participants Enrolled”

Drugs

EvaluationDrugModalityDoseRoute
Subject Belcesiran Unknown — Subcutaneous

Indications

alpha 1-antitrypsin deficiency